Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
PDF 40kWORD 18k
24 September 2019
E-002942-19
Question for written answer E-002942-19
to the Commission
Rule 138
Piernicola Pedicini (NI)

 Subject:  Antibiotics taken off the market

The Italian Medicines Agency (AIFA) has published further information about the safety of medicinal substances containing fluoroquinolone (ciprofloxacin, levofloxacin, moxifloxacin, pefloxacin, prulifloxacin, rufloxacin, norfloxacin, lomefloxacin) which may produce long-lasting, disabling and potentially permanent adverse side effects, mainly affecting the tendons, muscles or joints and the nervous system.

AIFA has announced, therefore, that medicines containing cinoxacin, flumequine, nalidixic acid and pipemidic acid will be withdrawn from sale.

The German Federal Institute for Drugs and Medical Devices (BfArM) asked the European Medicines Agency (EMA) in 2017 to re-evaluate these medicines, which it did, but this was after it had already given the green light to their being marketed within the EU. In view of that fact, and the final assessments issued by EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) in 2018 and its Committee for Human Medical Products (CHMP), can the Commission answer the following:
1. Which studies were examined during the marketing authorisation procedures conducted prior to the re-evaluation requested in 2017?
2. Was sufficient weight given to the permanent, disabling adverse side effects on the tendons, muscles and joints and on the nervous system when those studies were examined?
3. Is the Commission going to give patients a straightforward, unambiguous explanation of exactly which medicines will be taken off the market and when?
Original language of question: IT 
Last updated: 8 October 2019Legal notice